Ricardo Perdigão Henriques, PhD in

Ricardo Perdigão Henriques, PhD

Login to view DISC.
Board Observer at Mondego Bio
📍 Lisbon Metropolitan Area, Portugal

Dr. Ricardo Perdigão Henriques is a Harvard and MIT-educated scientist turned venture capitalist, now Managing Partner at Biovance Capital. He focuses on early-stage biotech investments across Europe, with a notable success being the investment in CellmAbs, which resulted in Portugals largest-ever biotech deal upon its sale to BioNTech. Colleagues describe him as a visionary leader with integrity.

Having developed his career in both the USA and Portugal, Ricardo is passionate about elevating the Portuguese biotech ecosystem. He actively works to attract international investors to the region. He also dedicates time to education, teaching a venture capital course to Masters students at the University of Coimbra, mentoring the next generation of innovators.

He orchestrated the largest biotech transaction in Portugals history with the sale of oncology startup CellmAbs to BioNTech.

Read the full overview →
Current Role
Board Observer
Job Level
Leadership
Location
Lisbon Metropolitan Area, Portugal
Personality Overview

How Ricardo shows up

Communication Style
Decision Approach
Work Preference

Behavioral traits and communication patterns that shape how this person evaluates opportunities, builds trust, and makes decisions in professional settings.

Login to view personality overview.
Priorities

Topics Ricardo cares about

Early-Stage Biotech
As Managing Partner of Biovance Capital, he leads a €60M fund specifically targeting investments in early-stage drug development companies across Europe.
Portuguese Biotech
Vocal about his mission to attract world-class scientists and investors to Portugal, strengthening the country's position in the life sciences.
+5 more topics Login to view topics
Career

Work history

8-2025
Board Observer
Mondego Bio
2023
Managing Partner and Co-Founder
Biovance Capital
2021
Board Member
VAXDYN SL
2019 - 5-2024
Board Member
CellmAbs
2019 - 4-2024
Chief Executive Officer
Bionova Capital
In the press

Media appearances

Biovance Capital leads Series A Financing in Mondego Bio together with Orbimed and Torrey Pines. Featured in PR Newswire
See now
Biovance Capital Partners announces first closing of its new biotech fund at $51 million. Featured in P‑Bio
+3 more appearances Login to view media
Education
2009 - 2015
Invited PhD Student
Harvard Medical School
2011 - 2011
Mini-MBA Program in Entrepreneurial Finance
Harvard University
Social presence
in
Behavioral profile

DISC profile (public)

DISC behavioral profile

Dominance, influence, steadiness, and calculativeness scores with guidance on how this person prefers to communicate and decide.

Login to view DISC.

More profiles

Discover additional public profiles from our index.

Unlock the full playbookSee exactly how to sell to Ricardo. Free, 10 seconds.